Literature DB >> 5270679

Daunorubicin in acute leukaemia.

R L Souhami, T A Prankerd.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5270679      PMCID: PMC2467022          DOI: 10.1136/pgmj.46.535.272

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  5 in total

1.  Rubidomycin. A new agent active in the treatment of acute lymphoblastic leukaemia.

Authors:  C Jacquillat; M Boiron; M Weil; J Tanzer; Y Najean; J Bernard
Journal:  Lancet       Date:  1966-07-02       Impact factor: 79.321

2.  Acute lymphoblastic leukaemia treated with a combination of prednisone, vincristine, and rubidomycin. Value of pathogen-free rooms.

Authors:  G Mathé; M Hayat; L Schwarzenberg; J L Amiel; M Schneider; A Cattan; J R Schlumberger; C Jasmin
Journal:  Lancet       Date:  1967-08-19       Impact factor: 79.321

3.  Daunorubicin in the treatment of acute myelocytic leukaemia.

Authors:  M Boiron; M Weil; C Jacquillat; J Tanzer; D Levy; C Sultan; J Bernard
Journal:  Lancet       Date:  1969-02-15       Impact factor: 79.321

4.  [Trial of treatment of acute lymphoblastic and myeloblastic leukemias by a new antibiotic: rubidomycin (RP 13,057). Study of 61 cases].

Authors:  J Bernard; C Jacquillat; M Boiron; Y Najean; M Seligmann; J Tanzer; M Weil; P Lortholary
Journal:  Presse Med       Date:  1967-04-22       Impact factor: 1.228

5.  Rubidomycin in acute leukaemia in adults.

Authors:  J S Malpas; R B Scott
Journal:  Br Med J       Date:  1968-07-27
  5 in total
  1 in total

1.  Candidate agents for papillary thyroid cancer identified by gene expression analysis.

Authors:  Wei Zhu; Chen Li; Zhilong Ai
Journal:  Pathol Oncol Res       Date:  2013-03-22       Impact factor: 3.201

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.